Dataset Information


Imatinib targeting of KIT-mutant oncoprotein in melanoma

ABSTRACT: Metastatic melanoma is an aggressive treatment-refractory malignancy. Recently, c-Kit mutations were discovered in certain mucosal melanomas. A clinical trial was initiated with the c-Kit inhibitor imatinib mesylate. The first treated patient experienced dramatic clinical improvement within days, followed by major responses by PET/CT four weeks later at all sites of metastatic disease. Several established mucosal melanoma cell lines exhibited imatinib sensitivity in a fashion correlating with c-Kit mutational status. Although c-Kit mutations are uncommon in cutaneous melanoma, they may arise in geographically distinct subsets for whom use of c-Kit targeted kinase inhibition should be considered in a rational therapeutic approach. Keywords: Whole genome copy number analysis Overall design: Copy number analysis using high-density SNP arrays to investigate genetic gains and losses involved in the genesis of mucosal and cutaneous melanoma. GSE8164_raw_copy_number_calls.xls contains raw copy number calls generated by dChip (build 5/2007) for GIST, K008, K029, M34, MEL1, MEL40, M6, and 5 Affymetrix controls (copy number identity 2 i.e. normal), which are available on the HapMAP site.

INSTRUMENT(S): [Mapping250K_Sty] Affymetrix Mapping 250K Sty2 SNP Array

ORGANISM(S): Homo sapiens  

SUBMITTER: Stephen Hodi  

PROVIDER: GSE8164 | GEO | 2008-12-24



Similar Datasets

2008-12-23 | E-GEOD-8164 | ArrayExpress
2013-01-01 | S-EPMC4878082 | BioStudies
2009-01-01 | S-EPMC3125991 | BioStudies
2009-01-01 | S-EPMC3346953 | BioStudies
2020-01-01 | S-EPMC7140320 | BioStudies
2016-01-01 | S-EPMC5035787 | BioStudies
1000-01-01 | S-EPMC5669918 | BioStudies
1000-01-01 | S-EPMC524218 | BioStudies
2017-01-01 | S-EPMC5470740 | BioStudies
2017-01-01 | S-EPMC5522195 | BioStudies